|
Dr Louise Makin
Chief Executive Officer |
Louise Makin joined BTG as Chief Executive Officer in October 2004 and she is a non-executive director of Premier Foods plc. From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998. Louise has an MBA, and holds an MA in Natural Sciences and a PhD in Metallurgy from the University of Cambridge.
|
Rolf Soderstrom
Chief Financial Officer
|
Rolf Soderstrom, BA, ACA, joined BTG as Chief Financial Officer in December 2008 from Protherics PLC, where he was Finance Director from August 2007. From 2004, he was a Divisional Finance Director of Cobham plc, managing a portfolio of businesses across Europe and the USA. From 2000 he was a Director of Corporate Finance at Cable & Wireless plc. Prior to this, he worked in the Corporate Recovery and Corporate Finance Department of PricewaterhouseCoopers after qualifying as a Chartered Accountant.
|
Matthew Gantz
Executive Vice President, US
|
Matthew Gantz joined BTG in February 2009. He is Executive Vice President, US, with responsibility for BTG’s commercial operations in the US. Prior to BTG, Matthew was Founder and CEO of Acureon Pharmaceuticals, a specialty pharmaceutical company focused in the hospital areas of infectious diseases, transplant and ICU. Prior to Acureon, he was the President and CEO of Hydrabiosciences Inc, a privately held biotechnology company developing novel, ion channel medicines in the pain and cardiovascular area. From 2000 to 2003, Matthew was the VP Europe for Chiron’s Biopharmaceutical Division where he was directly responsible for $100+ million Infection Disease and Oncology business. From 1996 to 2000 he was the GM for PathoGenesis Europe before the company was acquired by Chiron. Prior to Chiron/PathoGenesis, Matthew held a variety of US sales and marketing roles at Abbott Laboratories Diagnostics Division. Matthew served as an infantry officer in the US Marine Corps, earned his MBA from Harvard and his undergraduate degree from Princeton University.
|
|
Dr Guenter Janhofer
Head of Development
|
Guenter R. Janhofer joined BTG in March 2009 as Head of Development. Guenter has more than 25 years of experience in the pharmaceutical industry across all phases of clinical development from Phase I to end-stage life-cycle management and across a wide variety of therapeutic areas, including cardiovascular, metabolic, neuroscience, infectious diseases, respiratory, osteoporosis and oncology. Having started as Medical Director of Desitin Pharmaceuticals in Hamburg, Germany, he later served Merck & Co., Inc. in functions of growing complexity and scope, both at the subsidiary and at the headquarters’ level. He most recently served as Vice President of Global Medical and Scientific Affairs and has been instrumental of bringing Internet technology to Merck’s clinical development process. Guenter holds an MD degree from Hamburg University, PhDs in Climatology and Medicine from the University of Bochum and a post-doc degree (Habilitation) from the University of Technology in Berlin, where he is a faculty member at the School of Public Health.
|
Dr Richard Mason
Head of Business Development
|
Richard Mason joined BTG in April 2009 as Head of Business Development. He joined from venture capital firm Advent Venture Partners where, as Executive-in-Residence, he undertook CEO assignments at portfolio life sciences companies, both listed and private. Previously Richard was Senior Vice President Business Development at Cambridge Antibody Technology plc. Richard qualified in medicine from the Medical College of St. Bartholomew’s Hospital, University of London and subsequently worked for the NHS in internal and emergency medicine at several London teaching hospitals. He is a member of the Royal College of Physicians and also holds a BSc in Immunology from University College London and an MBA from the Judge Business School, University of Cambridge, where he is currently an Honorary Fellow. He is on the board of the monoclonal antibody journal mAbs.
|
James Christie
Operations Director
|
James Christie, BSc, MBA, joined BTG in December 2008 following the merger of BTG and Protherics. He entered the biopharmaceutical industry in 1980 and has worked with GSK, Celltech and Centocor BV, before joining Protherics in 1998. He was appointed to the Protherics Board in September 1999. James was instrumental in building the Polyclonal Antibody business for Protherics and was a key individual in securing the AstraZeneca-Protherics Sepsis deal in 2005. James currently has management responsibility for the Manufacturing, Engineering, Quality, Process Development and Technical Support operations in Australia, UK and the USA.
|
|
Yvonne Rogers
Director of HR & IT
|
Yvonne Rogers joined BTG in December 2008 following the merger of BTG and Protherics. She joined Protherics in November 2003 to build Protherics’ Human Resources and Training and Development activities across the global company. A graduate of the Chartered Institute of Personnel and Development, she has spent over 20 years as a generalist Human Resources professional.
|
|